Aiming to accelerate drug development with AI, NVIDIA and Eli Lilly jointly set up a laboratory, investing $1 billion.

```

Nvidia and pharmaceutical giant Eli Lilly announced on Monday that the two companies will jointly invest $1 billion to establish a laboratory in San Francisco focused on using artificial intelligence to accelerate drug development.

Eli Lilly CEO David Ricks said: "Combining our vast data scale and scientific knowledge with Nvidia's computing power and model-building expertise has the potential to completely reshape the way we know drug development."

This $1 billion investment will be completed within five years and will be used for the laboratory's infrastructure, computing power, and talent development. Nvidia engineers will work alongside Eli Lilly's experts in biology, science, and medicine to generate large-scale data and build AI models to advance new drug development. The two companies stated that the laboratory's work will begin early this year.

This investment is a further deepening of the existing cooperation between Nvidia and Eli Lilly. Last October, Eli Lilly said it was using Nvidia's AI systems to build an "AI factory" to accelerate drug development.

On Monday, Eli Lilly's stock price rose slightly and has increased by nearly 34% over the past year, surpassing the S&P 500's 19% gain over the same period. The company became the first healthcare company with a $1 trillion market cap last November. Meanwhile, Nvidia has become the world's highest-valued company and is set to become the first company with a $5 trillion market cap in 2025.

The Nvidia and Eli Lilly project is the latest in a series of investments and deals across the entire AI ecosystem—some of which have attracted attention on Wall Street and sparked concerns about an AI bubble.

In the healthcare sector, Nvidia has also invested in biotech company Recursion and established partnerships with several industry-leading organizations, including Eli Lilly's rival Novo Nordisk, Mayo Clinic, Illumina, and IQVIA, to apply AI to medical research and drug development.

Nvidia CEO Jensen Huang said in a statement on Monday: "AI is transforming every industry, and its most profound impact will be in the life sciences."

Risk Warning and DisclaimerThe market has risks, and investments need to be made cautiously. This article does not constitute personal investment advice, nor does it take into account the special investment objectives, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular situation. Investing based on this is at your own risk.```